Verition Fund Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-7,500
Closed -$480K – 2243
2026
Q2
$480K Buy
+7,500
New +$389K ﹤0.01% 1651
2025
Q3
– Sell
-21,368
Closed -$591K – 3893
2025
Q2
$591K Sell
21,368
-6,625
-24% -$169K ﹤0.01% 2828
2025
Q1
$622K Sell
27,993
-26,735
-49% -$550K ﹤0.01% 2435
2024
Q4
$1.08M Buy
54,728
+27,944
+104% +$638K ﹤0.01% 1992
2024
Q3
$669K Buy
+26,784
New +$652K ﹤0.01% 2140
2020
Q2
– Sell
-19,700
Closed -$305K – 1115
2020
Q1
$305K Buy
+19,700
New +$308K 0.01% 424

Other funds holding KNSA

Verition Fund Management's KNSA Position: Q3 2026 in Review

Verition Fund Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2026, closing a stake of 7,500 shares — an estimated $480K sold.

Verition Fund Management first reported a position in KNSA in Q1 2020 and held it in 6 quarters. The position peaked at $1.08M in Q4 2024. 300 funds tracked by Wall St. Rank hold KNSA as of Q3 2026.

  • Verition Fund Management reported no remaining Kiniksa Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Verition Fund Management sold 7,500 Kiniksa Pharmaceuticals shares in Q3 2026, an estimated $480K.
  • Verition Fund Management first reported a position in Kiniksa Pharmaceuticals in Q1 2020 and held it in 6 quarters.
  • Verition Fund Management's Kiniksa Pharmaceuticals position peaked at $1.08M in Q4 2024.
  • 300 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2026.

Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.